$ONCO
Onconetix, Inc. Stock $onco

$onco Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024107088 Filed on December 10, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$406.9K	$0.00
YoY Change
Cost Of Revenue		$301.4K
YoY Change
Gross Profit		$105.4K
YoY Change
Gross Profit Margin		25.91%
Selling, General & Admin		$2.642M	$4.269M
YoY Change		-38.11%	58.44%
% of Gross Profit		2506.23%
Research & Development		$109.4K	$219.2K
YoY Change		-50.12%	-81.35%
% of Gross Profit		103.75%
Depreciation & Amortization			$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses		$2.751M	$4.488M
YoY Change		-38.7%	15.98%
Operating Profit		-$2.646M	-$4.488M
YoY Change		-41.05%	15.98%
Interest Expense			$269.1K
YoY Change			8665.37%
% of Operating Profit
Other Income/Expense, Net		-$1.238M	-$858.8K
YoY Change		44.14%	-28056.54%
Pretax Income		-$3.884M	-$5.350M
YoY Change		-27.41%	38.36%
Income Tax		-$56.00K
% Of Pretax Income
Net Earnings		-$3.827M	-$5.347M
YoY Change		-28.42%	38.28%
Net Earnings / Revenue		-940.72%
Basic Earnings Per Share		-$2.93	-$0.31
Diluted Earnings Per Share		-$2.93	-$0.31
COMMON SHARES
Basic Shares Outstanding	8.295M shares	29.79M shares	17.52M shares
Diluted Shares Outstanding		1.306M shares	17.52M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$7.650M
YoY Change		-73.74%
Cash & Equivalents	$341.5K	$7.654M
Short-Term Investments
Other Short-Term Assets		$470.0K
YoY Change		-46.6%
Inventory	$121.8K	$1.419M
Prepaid Expenses		$467.7K
Receivables	$98.03K
Other Receivables	$0.00
Total Short-Term Assets	$1.048M	$9.541M
YoY Change	-89.02%	-68.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$69.32K	$12.50K
YoY Change	454.4%	-21.53%
Goodwill	$38.86M
YoY Change
Intangibles	$21.41M	$17.91M
YoY Change	19.59%
Long-Term Investments
YoY Change
Other Assets		$420.0K
YoY Change		347.05%
Total Long-Term Assets	$60.87M	$18.34M
YoY Change	231.89%	16591.89%
TOTAL ASSETS
Total Short-Term Assets	$1.048M	$9.541M
Total Long-Term Assets	$60.87M	$18.34M
Total Assets	$61.92M	$27.88M
YoY Change	122.08%	-7.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.112M	$3.176M
YoY Change	29.47%	280.71%
Accrued Expenses	$1.338M	$1.539M
YoY Change	-13.06%	-56.72%
Deferred Revenue
YoY Change
Short-Term Debt		$12.92M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.36M	$17.65M
YoY Change	-1.64%	298.19%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.36M	$17.65M
Total Long-Term Liabilities		$0.00
Total Liabilities	$20.90M	$17.65M
YoY Change	18.4%	298.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$86.00M	-$34.44M
YoY Change	149.74%	113.11%
Common Stock	$83.00	$183.00
YoY Change	-54.64%	24.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$625.8K
YoY Change
Treasury Stock Shares
Shareholders Equity	$33.91M	$10.24M
YoY Change
Total Liabilities & Shareholders Equity	$61.92M	$27.88M
YoY Change	122.08%	-7.56%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$3.827M	-$5.347M
YoY Change	-28.42%	38.28%
Depreciation, Depletion And Amortization		$0.00
YoY Change		-100.0%
Cash From Operating Activities		-$3.040M
YoY Change		66.2%
INVESTING ACTIVITIES
Capital Expenditures		$50.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$220.0K
YoY Change
Cash From Investing Activities		$180.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		1.300M
YoY Change		-85.1%
NET CHANGE
Cash From Operating Activities		-3.040M
Cash From Investing Activities		180.0K
Cash From Financing Activities		1.300M
Net Change In Cash		-1.560M
YoY Change		-122.63%
FREE CASH FLOW
Cash From Operating Activities		-$3.040M
Capital Expenditures		$50.00K
Free Cash Flow		-$3.090M
YoY Change		68.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2023Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2024Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41294
	dei	Entity Registrant Name EntityRegistrantName	Onconetix, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2262816
	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 E. Fifth Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1900
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cincinnati
	dei	Entity Address State Or Province EntityAddressStateOrProvince	OH
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	45202
	dei	City Area Code CityAreaCode	(513)
	dei	Local Phone Number LocalPhoneNumber	620-4101
	dei	Security12b Title Security12bTitle	Common stock, $0.00001 par value
	dei	Trading Symbol TradingSymbol	ONCO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8294734	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	341495	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4554335	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	98030	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	149731	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	121834	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	364052	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	486580	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	770153	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1047939	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5838271	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	17423	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	69317	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60654	usd
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	366113	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	366113	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	160016	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	148542	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21414795	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25410887	usd
CY2024Q3	us-gaap	Goodwill Goodwill	38861238	usd
CY2023Q4	us-gaap	Goodwill Goodwill	55676142	usd
CY2024Q3	us-gaap	Assets Assets	61919418	usd
CY2023Q4	us-gaap	Assets Assets	87518032	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4112392	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5295114	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1337663	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2199867	usd
CY2024Q3	onco	Note Payable Net Of Debt Discount NotePayableNetOfDebtDiscount	10048	usd
CY2023Q4	onco	Note Payable Net Of Debt Discount NotePayableNetOfDebtDiscount	381627	usd
CY2024Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	9839677	usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	9618373	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127738	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	74252	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	124631	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2641	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	17356101	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17190247	usd
CY2024Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	118450	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	118857	usd
CY2024Q3	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	522174	usd
CY2023Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	556296	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32279	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	74290	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2867794	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3073781	usd
CY2024Q3	us-gaap	Liabilities Liabilities	20896798	usd
CY2023Q4	us-gaap	Liabilities Liabilities	21877471	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	64236085	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8326281	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	571033	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8313347	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	558099	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	83	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	6	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	119563869	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49429031	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12934	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12934	shares
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	625791	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	625791	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86038875	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56786194	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1012557	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2380920	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	33911843	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5602028	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	7110777	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	7006504	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41022620	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1404476	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61919418	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87518032	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	406859	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1812140	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	301445	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1417010	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	105414	usd
	us-gaap	Gross Profit GrossProfit	395130	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2641916	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4268845	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8599642	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8337615	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109365	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	219238	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	154649	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2148327	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	3530716	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15453000	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3500000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	2751281	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	4488083	usd
	us-gaap	Operating Expenses OperatingExpenses	27738007	usd
	us-gaap	Operating Expenses OperatingExpenses	13985942	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2645867	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4488083	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27342877	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13985942	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	153302	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	534245	usd
CY2024Q3	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	231656	usd
CY2023Q3	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	269097	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	625084	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	483093	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-490000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-490000	usd
CY2024Q3	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability	928400	usd
	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability	950000	usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-30448	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	99728	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-30448	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	99787	usd
CY2024Q3	us-gaap	Other Income OtherIncome	44988	usd
	us-gaap	Other Income OtherIncome	41894	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1237922	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-858825	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2036987	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1072880	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3883789	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5346908	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29379864	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15058822	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-56384	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-127183	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3827405	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5346908	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29252681	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15058822	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.93
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.93
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.21
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-36.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-36.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-36.61
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-36.61
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1306146	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1306146	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	438039	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	438039	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	806743	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	806743	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	411303	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	411303	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3827405	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5346908	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29252681	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15058822	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-3488514	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1392630	usd
CY2024Q3	onco	Change In Pension Benefit Obligation ChangeInPensionBenefitObligation	-97005	usd
	onco	Change In Pension Benefit Obligation ChangeInPensionBenefitObligation	24267	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-435896	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5346908	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30621044	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15058822	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1404476	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	52650	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4991144	usd
CY2024Q1	onco	Stock Issued During Period Value Of Changes In Pension Benefit Obligation StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation	154678	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11118572	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14497912	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	163	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-775	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-110000	usd
CY2024Q2	onco	Stock Issued During Period Value Of Changes In Pension Benefit Obligation StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation	-33406	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-14306704	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28728634	usd
CY2024Q3	onco	Issuance Of Common Stock And Warrants From Exercise Of Preferred Investment Options Net Of Issu IssuanceOfCommonStockAndWarrantsFromExerciseOfPreferredInvestmentOptionsNetOfIssu	765029	usd
CY2024Q3	onco	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	6155	usd
CY2024Q3	onco	Issuance Of Shares And Prefunded Warrants In Connection With Related Party Subscription Agree IssuanceOfSharesAndPrefundedWarrantsInConnectionWithRelatedPartySubscriptionAgree	5134247	usd
CY2024Q3	onco	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	64236085	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	45634	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3488514	usd
CY2024Q3	onco	Adjustments To Additional Paid In Capital Change In Pension Benefit Obligation AdjustmentsToAdditionalPaidInCapitalChangeInPensionBenefitObligation	-97005	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3827405	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41022620	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	22388002	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	185578	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	33454	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2846644	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19693482	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	459	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	272781	usd
CY2023Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	25527	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6865270	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13075925	usd
CY2023Q3	onco	Adjustments To Additional Paid In Capital Issuance Of Common Stock From Exercise Of Preferred Investment Options Net Of Issuance Costs AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsNetOfIssuanceCosts	2272838	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	129184	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	105402	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5346908	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10236441	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29252681	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15058822	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3500000	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	267019	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15453000	usd
	onco	Impairment Of Entadfi Assets ImpairmentOfENTADFIAssets	3530716	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	371578	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	483093	usd
	onco	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	400000	usd
	onco	Loss On Related Party Receivable LossOnRelatedPartyReceivable	265648	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-490000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	612046	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4886	usd
	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability	950000	usd
	us-gaap	Pension Expense PensionExpense	16502	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	98228	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	563761	usd
	onco	Interest Accrued On Note Payable InterestAccruedOnNotePayable	230532	usd
	onco	Interest Accrued On Note Payable Related Party InterestAccruedOnNotePayableRelatedParty	134247	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	356637	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	35730	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-99787	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-127183	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-49079	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	113102	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	299272	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-70563	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	9526	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7749	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16882	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1242071	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1418048	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1072781	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-976871	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9578169	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9269131	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	79771	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	6079771	usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	3500000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	51744	usd
	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	229798	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24597	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3300	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24597	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9864613	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	5000000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	853550	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	942307	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1000000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	922749	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	2298675	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	163	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	459	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6155	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	205093	usd
	onco	Payments For Purchase Of Treasury Shares PaymentsForPurchaseOfTreasuryShares	58981	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5440310	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1035060	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-50384	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4212840	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18098684	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4554335	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25752659	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	341495	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7653975	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	19658	usd
	us-gaap	Noncash Or Part Noncash Acquisition Inventory Acquired1 NoncashOrPartNoncashAcquisitionInventoryAcquired1	12947000	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	1874777	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	2613011	usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	150000	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	157720	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	25837	usd
	onco	Warrants Issued For Settlement Of Contingent Warrants WarrantsIssuedForSettlementOfContingentWarrants	129184	usd
	onco	Deferred Offering Costs Previously Prepaid DeferredOfferingCostsPreviouslyPrepaid	-11020	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	64236085	usd
	onco	Exerciseofprefundedwarrants Exerciseofprefundedwarrants	7	usd
	us-gaap	Stock Issued1 StockIssued1	5	usd
	onco	Restricted Stock Forfeitures RestrictedStockForfeitures	-2	usd
	us-gaap	Notes Issued1 NotesIssued1	5134247	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	87864	usd
CY2024Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-forty (1:40).
CY2024Q3	us-gaap	Cash Cash	300000	usd
CY2024Q3	onco	Working Capital Deficit WorkingCapitalDeficit	16300000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9600000	usd
CY2024Q4	onco	Additional Cash AdditionalCash	400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to accounting for acquisitions, valuation of inventory, the useful life of the amortizable intangible assets, estimates of future cash flows used to evaluate impairment of intangible assets, assumptions related to the pension benefit obligation, assumptions related to the related party subscription agreement liability, assumption related to note payables, and accounting for income taxes. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	124631	usd
CY2024Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1938631	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2641	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	866641	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	400000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1800000	usd
CY2024Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	98000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	150000	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	97915	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	139208	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	194805	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	23919	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	30039	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	121834	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	364052	usd
CY2024Q2	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	400000	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	312461	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	122004	usd
CY2024Q3	us-gaap	Prepaid Rent PrepaidRent	71763	usd
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	312551	usd
CY2023Q4	onco	Prepaids Research And Development PrepaidsResearchAndDevelopment	89195	usd
CY2024Q3	onco	Prepaid Professional Fees PrepaidProfessionalFees	38208	usd
CY2023Q4	onco	Prepaid Professional Fees PrepaidProfessionalFees	70708	usd
CY2024Q3	onco	Prepaid Vat Taxes Receivable PrepaidVATTaxesReceivable	53458	usd
CY2024Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	10690	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	175695	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	486580	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	770153	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	25447699	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	3296644	usd
	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	75907	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	22075148	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-36812	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	-595759	usd
	onco	Accumulated Amortization Foreign Currency Translation AccumulatedAmortizationForeignCurrencyTranslation	-27782	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-660353	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25410887	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21414795	usd
CY2024Q3	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P15Y
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	198000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	596000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	200000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	213239	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	852955	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	852955	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	852955	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	852955	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	8508911	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12133970	usd
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P14Y2M19D
CY2023Q4	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	9300000	usd
CY2024Q3	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	9300000	usd
CY2024Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5200000	usd
CY2024Q2	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	10300000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15500000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	55676142	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15453000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	1361904	usd
CY2024Q3	us-gaap	Goodwill Goodwill	38861238	usd
CY2024Q3	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	255679	usd
CY2023Q4	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	487579	usd
CY2024Q3	onco	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	362839	usd
CY2023Q4	onco	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	616707	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	228282	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	550415	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	220331	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	265849	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	93787	usd
CY2024Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	40000	usd
CY2023Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	60530	usd
CY2024Q3	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	230532	usd
CY2023Q4	onco	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	125000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1337663	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2199867	usd
	onco	Royalty Sales Percentage RoyaltySalesPercentage	0.06	pure
CY2024Q3	onco	Sales Payments Amount SalesPaymentsAmount	22500000	usd
CY2024Q2	us-gaap	Noninterest Bearing Deposit Liabilities NoninterestBearingDepositLiabilities	5000000	usd
	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	6000000	usd
	us-gaap	Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable	12947000	usd
	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	79771	usd
	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	19026771	usd
CY2024Q3	us-gaap	Inventory Adjustments InventoryAdjustments	300000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3500000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	14700000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	1	pure
	us-gaap	Business Acquisition Pro Forma Information Description BusinessAcquisitionProFormaInformationDescription	(i) $3.5 million in cash at signing of the WraSer APA; (ii) $4.5 million in cash on the later of (x) 90 days after the signing of the WraSer APA or (y) the date that all closing conditions under the WraSer APA are met or otherwise waived (the “WraSer Closing Date”); (iii) 25,000 shares of the Company’s common stock (the “Closing Shares”) issuable on the WraSer Closing Date, and (iv) $500,000 in cash one year from the WraSer Closing Date.
CY2024Q3	onco	Initial Payment Amount InitialPaymentAmount	3500000	usd
	onco	Payments Payments	3500000	usd
CY2024Q3	us-gaap	Deposits Deposits	3500000	usd
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	1100000	usd
CY2024Q2	us-gaap	Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Costs BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts	500000	usd
CY2023Q4	onco	Voting Interest Percentage VotingInterestPercentage	1	pure
CY2023Q4	onco	Stock Issued During Period Shares Issuance Of Common Stock And Series B Preferred Stock In Connection With Pmx Transaction StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction	91874	shares
	onco	Business Acquisition Description Of Acquired BusinessAcquisitionDescriptionOfAcquired	i) the Company obtained 100% of the outstanding common stock and voting interest of PMX, (ii) at closing of the PMX Transaction, the PMX shareholders were issued approximately 17% of Onconetix’s outstanding common stock and none of the former PMX shareholders held more than 5% of Onconetix’s common stock individually, (iii) the composition of executive management and the governing body did not change sufficiently to give PMX or its former shareholders control over these functions within Onconetix, and (iv) Onconetix was significantly larger when considering both total assets and operations.
	onco	Royalty Rate RoyaltyRate	0.06	pure
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1500000	usd
CY2023Q3	us-gaap	Long Term Debt Maturity Date LongTermDebtMaturityDate	2025-07-14
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	400000	usd
CY2024Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1100000	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1800000	usd
	onco	Milestone Payments MilestonePayments	2500000	usd
	onco	Additional Milestone Payment AdditionalMilestonePayment	500000	usd
	onco	Payable Average Discount Rate Percentage PayableAverageDiscountRatePercentage	0.082	pure
CY2023Q3	onco	Cash Payment To The Seller CashPaymentToTheSeller	1000000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	490000	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	142749	shares
	onco	Registered Shares Of Common Stock RegisteredSharesOfCommonStock	130321	shares
CY2024Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	10000	usd
	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.15	pure
	onco	Percentage Of Net Proceeds PercentageOfNetProceeds	0.10	pure
CY2024Q3	us-gaap	Investment Interest Rate Paid In Cash InvestmentInterestRatePaidInCash	0.10	pure
	onco	Percentage Monthly Payments Equal PercentageMonthlyPaymentsEqual	0.25	pure
	onco	Percentage Of Monthly Payments Equal Original Forbearance Agreement PercentageOfMonthlyPaymentsEqualOriginalForbearanceAgreement	0.15	pure
	onco	Payment Of Net Proceeds Percentage PaymentOfNetProceedsPercentage	0.20	pure
	onco	Percentage Of Increased Original Forbearance Agreement PercentageOfIncreasedOriginalForbearanceAgreement	0.10	pure
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	10000	usd
CY2024Q3	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	200000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	500000	usd
CY2024Q3	onco	Accrued Interestt AccruedInterestt	13424	shares
CY2024Q3	onco	Pre Funded Warrants PreFundedWarrants	0.3
CY2024Q3	onco	Exercisee Of Prefunded Warrants ExerciseeOfPrefundedWarrants	0.04
CY2024Q3	onco	Stock Issued During Period Shares Exercise Of Prefunded Warrants StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrants	3851	shares
CY2024Q3	us-gaap	Interest Expense Other InterestExpenseOther	200000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	500000	usd
	onco	Financing Fees FinancingFees	700000	usd
CY2024Q3	us-gaap	Investment Interest Rate Paid In Kind InvestmentInterestRatePaidInKind	0.0779	pure
CY2024Q3	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	200000	usd
CY2023Q4	onco	Units Issued During Period Shares New Issues UnitsIssuedDuringPeriodSharesNewIssues	500000	shares
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2024Q1	onco	Interest Rate Percentage InterestRatePercentage	0.04	pure
CY2024Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	500000	shares
CY2024Q3	onco	Conversion Of Additional Accrued Interest Shares ConversionOfAdditionalAccruedInterestShares	13424	shares
	us-gaap	Product Liability Contingency Third Party Recovery Percentage ProductLiabilityContingencyThirdPartyRecoveryPercentage	1	pure
CY2023	us-gaap	Product Liability Contingency Third Party Recovery Percentage ProductLiabilityContingencyThirdPartyRecoveryPercentage	0.55	pure
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Other Notes Payable OtherNotesPayable	3000000	usd
CY2024Q3	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	3000	shares
CY2023Q4	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	2696729	shares
CY2024Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	6741820	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8326281	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	571033	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8313347	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	558099	shares
CY2024Q3	onco	Purchase Aggregate Shares PurchaseAggregateShares	559397	shares
CY2024Q3	onco	Number Of Shares Issued NumberOfSharesIssued	186465	shares
CY2024Q3	onco	Contractual Term Of Warrant ContractualTermOfWarrant	P5Y
CY2024Q3	onco	Contractual Term Of Warrant ContractualTermOfWarrant	P5Y
CY2024Q3	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	372932	shares
CY2024Q3	onco	Remaining Term Of Contractual RemainingTermOfContractual	P2Y
CY2024Q3	onco	Remaining Term Of Contractual RemainingTermOfContractual	P2Y
CY2024Q3	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	900000	usd
	onco	Resale Registration Statement Number Of Days After The Date Of Inducement Letter ResaleRegistrationStatementNumberOfDaysAfterTheDateOfInducementLetter	P60D
	us-gaap	Management And Service Fees Rate ManagementAndServiceFeesRate	0.01	pure
	us-gaap	Legal Fees LegalFees	50000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	35000	usd
	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	13054	shares
	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	7.5
	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.075	pure
	onco	Percentage Of Common Stock PercentageOfCommonStock	0.07	pure
CY2023Q3	onco	Shares Of Contingent Warrants SharesOfContingentWarrants	7459	shares
CY2023Q3	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	onco	Common Stock Percentage CommonStockPercentage	0.07	pure
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	158000	usd
CY2023Q3	onco	Shares Of Common Stock Issued SharesOfCommonStockIssued	62155	shares
CY2023Q3	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	43.6
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	124311	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	39375	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	22780	shares
	us-gaap	Management And Service Fees Rate ManagementAndServiceFeesRate	0.01	pure
	us-gaap	Legal Fees LegalFees	50000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	35000	usd
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	54.5
	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	1.3625
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	7459	shares
	onco	Aggregate Net Proceeds AggregateNetProceeds	2300000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3729	shares
CY2024Q3	us-gaap	Other Liabilities OtherLiabilities	26000	usd
CY2022Q4	srt	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	125000	shares
CY2022Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	1
CY2022Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	2
CY2023Q3	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	0	shares
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	1441	shares
CY2024Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	0	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	59000	usd
CY2023Q3	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare	40.8
CY2024Q3	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	112000	usd
CY2023Q1	onco	Fixed Commission Rate FixedCommissionRate	0.03	pure
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	583475	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.1
	onco	Underlying Warrants Outstanding Fair Value UnderlyingWarrantsOutstandingFairValue	5.2
CY2024Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	125000	usd
CY2024Q3	us-gaap	Option Indexed To Issuers Equity Settlement Alternatives Shares At Fair Value OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue	39158	shares
CY2023Q4	us-gaap	Option Indexed To Issuers Equity Settlement Alternatives Shares At Fair Value OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue	11188	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	43.2
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	53000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	220000	usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	137000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	616000	usd
CY2023Q2	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	3750	shares
CY2024Q1	onco	Restricted Shares Granted Vest Percentage RestrictedSharesGrantedVestPercentage	0.50	pure
CY2024Q3	onco	Restricted Shares Granted Vest Percentage RestrictedSharesGrantedVestPercentage	0.25	pure
CY2023Q2	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	636	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	6414	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	41.2
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	16668	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.38
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	4852	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	39.59
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	313	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	41
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	17917	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.15
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	12257	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.46
CY2024Q3	us-gaap	Shares Held In Employee Stock Option Plan Allocated SharesHeldInEmployeeStockOptionPlanAllocated	57997	shares
	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	3.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y11M19D
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45634	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	105402	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	97509	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	563761	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	88000	usd
CY2024Q3	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	129000	usd
CY2022Q2	us-gaap	Short Term Lease Payments ShortTermLeasePayments	14000	usd
	us-gaap	Payments For Rent PaymentsForRent	51000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	4000	usd
	onco	Percentage Of Subscription PercentageOfSubscription	0.02	pure
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	209000	usd
CY2023	us-gaap	Dividends Paidinkind DividendsPaidinkind	159000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	50000	usd
CY2024Q3	us-gaap	Other Receivables OtherReceivables	363000	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2023Q4	onco	Subscription Agreement Pmx Investor Percentage SubscriptionAgreementPMXInvestorPercentage	0.05	pure
CY2024Q3	us-gaap	Other Expenses OtherExpenses	19000	usd
	us-gaap	Other Expenses OtherExpenses	54000	usd
CY2024Q3	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	19000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-56000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-127000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.13	pure
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	13674	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	34471	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	583475	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	197491	shares
	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	17917	shares
	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	8602	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	615066	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	240564	shares
	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.01	pure
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0145	pure
	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.01	pure
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0145	pure
	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.033	pure
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.03	pure
CY2024Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	24912	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	73356	usd
CY2024Q3	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	7638	usd
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	22489	usd
CY2024Q3	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	-5606	usd
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	17480	usd
CY2024Q3	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-3686	usd
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	11491	usd
CY2024Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	41842	usd
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	66874	usd
CY2024Q3	us-gaap	Pension Contributions PensionContributions	23000	usd
	us-gaap	Pension Contributions PensionContributions	66000	usd
CY2024Q4	onco	Funds Received FundsReceived	97000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2023Q3	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2024Q3	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
CY2023Q3	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q3	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability		usd
	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability		usd
CY2023Q3	us-gaap	Other Income OtherIncome		usd
	us-gaap	Other Income OtherIncome		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax		usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax		usd
CY2023Q3	onco	Change In Pension Benefit Obligation ChangeInPensionBenefitObligation		usd
	onco	Change In Pension Benefit Obligation ChangeInPensionBenefitObligation		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2024Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q1	onco	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	onco	Impairment Of Entadfi Assets ImpairmentOfENTADFIAssets		usd
	onco	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty		usd
	onco	Loss On Related Party Receivable LossOnRelatedPartyReceivable		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability		usd
	us-gaap	Pension Expense PensionExpense		usd
	onco	Interest Accrued On Note Payable InterestAccruedOnNotePayable		usd
	onco	Interest Accrued On Note Payable Related Party InterestAccruedOnNotePayableRelatedParty		usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	onco	Payments For Purchase Of Treasury Shares PaymentsForPurchaseOfTreasuryShares		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Noncash Or Part Noncash Acquisition Inventory Acquired1 NoncashOrPartNoncashAcquisitionInventoryAcquired1		usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1		usd
	onco	Warrants Issued For Settlement Of Contingent Warrants WarrantsIssuedForSettlementOfContingentWarrants		usd
	onco	Deferred Offering Costs Previously Prepaid DeferredOfferingCostsPreviouslyPrepaid		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
	onco	Exerciseofprefundedwarrants Exerciseofprefundedwarrants		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	onco	Restricted Stock Forfeitures RestrictedStockForfeitures		usd
	us-gaap	Notes Issued1 NotesIssued1		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2024Q3	onco	Prepaids Research And Development PrepaidsResearchAndDevelopment		usd
CY2023Q4	onco	Prepaid Vat Taxes Receivable PrepaidVATTaxesReceivable		usd
CY2024Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent		usd
CY2023Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest		usd
CY2024Q3	onco	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001782107

Files In Submission

Name	View Source	Status
0001213900-24-107088-index-headers.html	Edgar Link	pending
0001213900-24-107088-index.html	Edgar Link	pending
0001213900-24-107088.txt	Edgar Link	pending
0001213900-24-107088-xbrl.zip	Edgar Link	pending
ea0223979-10q_onconetix.htm	Edgar Link	pending
ea022397901ex31-1_onconetix.htm	Edgar Link	pending
ea022397901ex31-2_onconetix.htm	Edgar Link	pending
ea022397901ex32-1_onconetix.htm	Edgar Link	pending
ea022397901ex32-2_onconetix.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
onco-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
onco-20240930_lab.xml	Edgar Link	unprocessable
onco-20240930_cal.xml	Edgar Link	unprocessable
onco-20240930_def.xml	Edgar Link	unprocessable
ea0223979-10q_onconetix_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
onco-20240930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONCO
Onconetix, Inc. Stock $onco

2024 Q4 Form 10-Q Financial Statement

#000121390024107088 Filed on December 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONCO Onconetix, Inc. Stock $onco

2024 Q4 Form 10-Q Financial Statement

#000121390024107088 Filed on December 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONCO
Onconetix, Inc. Stock $onco